Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

Oncology · JCO

Ewing Sarcoma ctDNA Erratum Corrects Survival and Endpoint Labels

JCO erratum corrects two survival figures and one endpoint label in a ctDNA risk-classification study of Ewing sarcoma.

By Dr. Revathy Mohan V.R., MBBS · Oct 21, 2026 · 5 min read

Oncology·JCO

STELLAR Trial Erratum Corrects Figure 1A Curve Colors in Rectal Cancer Study

JCO issued an erratum for the STELLAR rectal cancer trial, correcting reversed TNT and CRT curve colors and…

Oct 21, 2026

Oncology·JCO

Ultra-low-dose nivolumab study draws statistical scrutiny in JCO correspondence

JCO correspondence examines statistical and methodological issues in evaluating ultra-low-dose nivolumab, with implications for how low-dose immunotherapy is…

Oct 21, 2026

Oncology·JCO

Mosperafenib Correspondence Challenges BRAF Resistance Assumptions

A JCO correspondence argues prior BRAF inhibitor exposure alone should not define resistance in the phase I mosperafenib…

Oct 21, 2026

Oncology·JCO

ctDNA Surveillance After Colorectal Cancer Resection Moves Toward Precision Follow-Up

JCO commentary examines how ctDNA-guided surveillance may refine follow-up after curative resection for stage I to III colorectal…

Oct 21, 2026

Oncology·JCO

TPO Receptor Agonists in GI Cancer CIT Move Toward Clinical Integration

A JCO commentary examines how thrombopoietin receptor agonists may fit into care for GI cancer patients with chemotherapy-induced…

Oct 21, 2026

Oncology·JCO

Oncology essay warns time toxicity is being repurposed by industry and payers

JCO essay warns that time toxicity is being used to advance industry, payer, and system goals while patient…

Oct 21, 2026

Oncology·JCO

Young Adult Lymphoma Survivorship, Grief, and Survivor’s Guilt in JCO Essay

A JCO personal essay on young adult stage IV lymphoma, remission, recurrence, and the emotional burden of surviving…

Oct 21, 2026

Oncology·JCO

Daraxonrasib in Pancreatic Cancer Raises First-Line Trial Design Questions

Daraxonrasib improved survival after prior therapy in pancreatic cancer, but first-line use, toxicity, resistance, and trial design remain…

Oct 21, 2026

Oncology·JCO

Pediatric ALL Mask Design Helped a Child Tolerate Cranial Irradiation

A child with ALL resisted sedation and immobilization until a tiger-painted radiation mask matched his world and restored…

Oct 21, 2026

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.